List of APIs/Active Pharmaceutical Ingredients Companies in South Korea - 6

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: www.bmikr.co.kr

Jeil Pharmaceutical - Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988. As of 2018, Jeil is constituted of 1143 employees and has sales amount reaching above 680 billion Korean wons. The Central R&D Center established in 1980 forms the core of the R&D activities of Jeil. Currently, as of 2018, the new drug development laboratory, the pharmacology & toxicology laboratory, the organic synthesis laboratory, the formulation laboratory, and the analysis laboratory are actively engaged in conducting research into the complete manufacture and ingredients of innovative new drugs, incrementally modified drugs, and generic drugs. Jeil’s factory established in 1986 and located in Yongin-si, Korea was accredited as fulfilling KGMP in 1987, and produces tablets, capsules, injections, finished pharmaceutical products including patches, and Active Pharmaceutical Ingredients(APIs) such as anti-biotic ingredients, etc. The construction of new factory with the most up-to-dated facilities, which complies with EU-GMP and US-GMP, has been completed in 2016. In May of 2018, Jeil established Pharmaceutical Technology Research Institute, a formulation and analysis lab, at Yongin Technovalley in Yongin-si, Korea to further improve and invest in research and development of Incrementally Modified Drug (IMD) and generic products. Jeil, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well. In the ingredients sector, Jeil exports synthetic ingredients such as Cefditoren Pivoxil, Epinastine HCl, etc. to Japan and China, while also supplies finished products such as Kefentech Plaster (Ketoprofen), Cilapenem Injection (Imipenem / Cilastatin Sodium), etc. to more than 40 countries in ASEAN, Central and South America, Africa, etc. Within the South Korean market, Jeil operates a well-trained MR organization to cover the nation-wide market based on science and evidence, and thereby has become a supplier of over 70 prescription drugs and over 30 over-the-counter drugs. Beginning in the period between 1970 and 1980, Jeil has engaged in technological partnerships (licensing) with global pharmaceutical companies to provide the domestic market with outstanding new drugs. It has also been the first Korean company to engage in co-promotion successfully with the globally renowned company Pfizer, executing a win-win strategy with our overseas collaborative partners and thus winning recognition as an advanced pharmaceutical company adapted to internationalized business practices. We thank all of the visitors to our Jeil’s homepage for their interest and encourage you to contact us for further business progress.

LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.

SHINPOONG PHARMACEUTICAL CO.,LTD. is a pharmaceuticals company based out of 733-23 Yoksam-Dong,Kangnam-Gu,Seoul, Seoul, South Korea.

***This page has moved and is no longer active. Please follow us @SK pharmteco for all company news and updates.*** SK biotek Ireland, an SK pharmteco company, is a contract development and manufacturing organization with almost 60 years of active pharmaceutical ingredients manufacturing experience. SK biotek Ireland is the most recent addition to the SK Group. Headquartered in Seoul, Korea, SK Group is ranked in the Top 100* on the Fortune Global 500 list; creating value by taking the initiative in the field of energy and chemicals, information, telecommunications, semiconductors; employing over 109,000 associates globally with annual revenue of US$100 billion. SK biotek Ireland, based in Swords, Co. Dublin, has over 300 associates on campus, comprising of scientists, chemists, engineers, quality professionals carrying out research, development, manufacturing and marketing roles. *2020 Fortune 500 List

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.